Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study

M S Dhingra, L Namazova-Baranova, J L Arredondo-Garcia, K-H Kim, K Limkittikul, W Jantarabenjakul, O Perminova, I A R Kobashi, C-W Bae, J Ojeda, J Park, D Chansinghakul, S B'Chir, D Neveu, M Bonaparte, E Jordanov, M S Dhingra, L Namazova-Baranova, J L Arredondo-Garcia, K-H Kim, K Limkittikul, W Jantarabenjakul, O Perminova, I A R Kobashi, C-W Bae, J Ojeda, J Park, D Chansinghakul, S B'Chir, D Neveu, M Bonaparte, E Jordanov

Abstract

Invasive meningococcal disease has high morbidity and mortality, with infants and young children among those at greatest risk. This phase III, open-label, randomised study in toddlers aged 12-23 months evaluated the immunogenicity and safety of meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT), a tetanus toxoid conjugated vaccine against meningococcal serogroups A, C, W and Y, when coadministered with paediatric vaccines (measles, mumps and rubella [MMR]; varicella [V]; 6-in-1 combination vaccine against diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b [DTaP-IPV-HepB-Hib] and pneumococcal conjugate vaccine [PCV13])(NCT03205371). Immunogenicity to each meningococcal serogroup was assessed by serum bactericidal antibody assay using human complement (hSBA). Vaccine safety profiles were described up to 30 days post-vaccination. A total of 1183 participants were enrolled. The proportion with seroprotection (hSBA ≥1:8) to each meningococcal serogroup at Day 30 was comparable between the MenACYW-TT and MenACYW-TT + MMR + V groups (≥92 and ≥96%, respectively), between the MenACYW-TT and MenACYW-TT + DTaP-IPV-HepB-Hib groups (≥90% for both) and between the MenACYW-TT and MenACYW-TT + PCV13 groups (≥91 and ≥84%, respectively). The safety profiles of MenACYW-TT, and MMR + V, DTaP-IPV-HepB-Hib, and PCV13, with or without MenACYW-TT, were generally comparable. Coadministration of MenACYW-TT with paediatric vaccines in toddlers had no clinically relevant effect on the immunogenicity and safety of any of the vaccines.

Keywords: Coadministration; MenACYW-TT; paediatric vaccines; toddlers.

Conflict of interest statement

MSD, EJ, JO, JP, DC, DN, SB'C and MB are employees of Sanofi Pasteur, and may hold shares and/or stock options in the company. JLA-G received Sanofi-Pasteur resources to carry out this project through his institution. LN-B, K-HK, KL, C-WB, IARK OP and WJ declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Proportion of participants with (a) hSBA meningococcal titres ≥1:8, (b) anti-measles antibody concentrations ≥225 mIU/ml, (c) anti-mumps antibody concentrations ≥10 mumps antibody units/ml, (d) anti-rubella concentrations ≥10 IU/ml and (e) anti-varicella antibody concentrations ≥5 glycoprotein ELISA antibody units/ml at Day 30 in participants randomised to MenACYW-TT + MMR + V, MenACYW-TT and MMR + V (PPAS). ELISA, enzyme-linked immunosorbent assay; hSBA, serum bactericidal antibody assay using human complement; MMR, measles, mumps and rubella vaccine; PPAS, per-protocol analysis set; V, varicella vaccine.
Fig. 2.
Fig. 2.
Proportion of participants with (a) hSBA meningococcal titres ≥1:8, (b) anti-tetanus antibody concentrations ≥0.1 and 1.0 IU/ml, (c) anti-diphtheria antibody concentrations ≥0.1 and 1.0 IU/ml, (d) anti-pertussis PT and FHA vaccine response*, (e) anti-polio 1, 2 and 3 antibody titres ≥1:8, (f) anti-Hep B antibody concentrations ≥10 and 100 mIU/ml, and (g) anti-PRP antibody concentrations ≥0.15 and 1.0 μg/ml at Day 30 in participants randomised to MenACYW-TT + DTaP-IPV-HepB-Hib, MenACYW-TT and DTaP-IPV-HepB-Hib (PPAS). DTaP-IPV-HepB-Hib, diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b vaccine; FHA, filamentous haemagglutinin; hSBA, serum bactericidal antibody assay using human complement; PPAS, per-protocol analysis set; PRP, polyribosyl-ribitol phosphate; PT, pertussis toxoid.
Fig. 3.
Fig. 3.
Proportion of participants with (a) hSBA meningococcal titres ≥1:8, and anti-pneumococcal antibody concentrations (b) ≥0.35 μg/ml and (c) ≥1.0 μg/ml to serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F at Day 30 in participants randomised to MenACYW-TT + PCV13, MenACYW-TT and PCV13 (PPAS). hSBA, serum bactericidal antibody assay using human complement; PCV13, pneumococcal conjugate vaccine; PPAS, per-protocol analysis set.

References

    1. Borrow R, et al. (2017) The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Review of Vaccines 16, 313–328.
    1. Olbrich KJ et al. (2018) Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infectious Diseases and Therapy 7, 421–438.
    1. Acevedo R et al. (2019) The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Review of Vaccines 18, 15–30.
    1. Pace D and Pollard AJ (2012) Meningococcal disease: clinical presentation and sequelae. Vaccine 30, B3–B9.
    1. Centers for Disease Control and Prevention. (2017) Enhanced Meningococcal Disease Surveillance Report. Available at .
    1. European Centre for Disease Prevention and Control. Invasive meningococcal disease: Annual Epidemiological Report for 2017. Available at .
    1. Vespa Presa J et al. (2019) Epidemiological burden of meningococcal disease in Latin America: a systematic literature review. International Journal of Infectious Diseases 85, 37–48.
    1. European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. Available at .
    1. Tsang RS et al. (2019) Increase in ST-11 serogroup W Neisseria meningitidis invasive meningococcal disease in Canada, 2016–2018. Canada Communicable Disease Report = Releve des Maladies Transmissibles au Canada 45, 164–169.
    1. Booy R et al. (2019) Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Human Vaccines & Immunotherapeutics 15, 470–480.
    1. Krone M et al. (2019) Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Eurosurveillance 24, 1800245.
    1. Bröker M et al. (2015) Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013. Human Vaccines & Immunotherapeutics 11, 2281–2286.
    1. Martin NV et al. (2016) Rise in invasive serogroup W meningococcal disease in Australia 2013–2015. Communicable Diseases Intelligence Quarterly Report 40, E454–e459.
    1. Presa J et al. (2019) Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review. Infectious Diseases and Therapy 8, 307–333.
    1. Findlow H and Borrow R (2016) Interactions of conjugate vaccines and co-administered vaccines. Human Vaccines & Immunotherapeutics 12, 226–230.
    1. Bröker M et al. (2017) Polysaccharide conjugate vaccine protein carriers as a “neglected valency” – potential and limitations. Vaccine 35, 3286–3294.
    1. Anez G et al. (2020) Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Human Vaccines & Immunotherapeutics 16, 1292–1298.
    1. Vesikari T et al. (2020) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a phase II randomized study. Human Vaccines & Immunotherapeutics 16, 1306–1312.
    1. Kirstein J et al. (2020) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a phase II randomized study. Human Vaccines & Immunotherapeutics 16, 1299–1305.
    1. Esteves-Jaramillo A et al. (2020) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: a phase III randomized study. Vaccine 38, 4405–4411.
    1. Dhingra MS et al. (2020) Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine 38, 5194–5201.
    1. Baccarini CI et al. (2020) Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-naïve children 2-9 years of age: a phase III, randomized study. The Pediatric Infectious Disease Journal 39, 955–960.
    1. van der Vliet D et al. (2021) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) versus a licensed quadrivalent meningococcal conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomized study. Epidemiology and Infection 149, e50.
    1. Chang LJ et al. (2020) A phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine 38, 3560–3569.
    1. World Health Organization, WHO vaccine-preventable diseases: monitoring system. 2020 global summary. Available at . Accessed 15 October 2020.
    1. Maslanka SE et al. (1997) Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group. Clinical and Diagnostic Laboratory Immunology 4, 156–167.
    1. Pina LM et al. (2012) Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. The Pediatric Infectious Disease Journal 31, 1173–1183.
    1. Tregnaghi MW, Zambrano B and Santos-Lima E (2011) Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4–, and 6-month-old argentinean infants. The Pediatric Infectious Disease Journal 30, e88–e96.
    1. Shehab ZM, Brunell PA and Cobb E (1984) Epidemiological standardization of a test for susceptibility to mumps. Journal of Infectious Diseases 149, 810–812.
    1. Johnson CE et al. (1996) Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. Eleven to thirteen years. The Pediatric Infectious Disease Journal 15, 687–692.
    1. Keller PM et al. (1986) Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. Journal of Virological Methods 14, 177–188.
    1. Wasmuth EH and Miller WJ (1990) Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. Journal of Medical Virology 32, 189–193.
    1. Provost PJ et al. (1991) Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 9, 111–116.
    1. Keshavan P et al. (2018) An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Expert Review of Vaccines 17, 865–880.
    1. Gasparini R et al. (2016) Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration. The Pediatric Infectious Disease Journal 35, 81–93.
    1. Assaf-Casals A and Dbaibo G (2016) Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): a review of its immunogenicity, safety, co-administration, and antibody persistence. Human Vaccines & Immunotherapeutics 12, 1825–1837.
    1. Javadekar B et al. (2018) Safety and immunogenicity of two doses of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in Indian and Russian children aged 9 to 17 months. Indian Pediatrics 55, 1050–1055.
    1. Cutland CL et al. (2018) Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: a phase III, open-label, randomised study. Vaccine 36, 1908–1916.
    1. Lawrence GL et al. (2016) Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme. Epidemiology and Infection 144, 2382–2391.
    1. Trotter CL et al. (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364, 365–367.
    1. Jafri RZ, et al. (2013) Global epidemiology of invasive meningococcal disease. Population Health Metrics 11, 17.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다